Macrophage Therapeutics Announces Manocept™ Results in Kaposi’s Sarcoma Studies to Be Presented at the American Associati...

Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that a presentation of Manocept™ data from Kaposi’s sarcoma studies is scheduled at the American Association of Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, PA from April 18 - 22, 2015. This research, led by Michael S. McGrath, M.D, Ph.D. and Toby Maurer, M.D., Kaposi’s sarcoma and HIV experts, at the University of California San Francisco, highlights both ex vivo and in vivo results in support of Manocept targeting of macrophages and tumor cells. Details of the presentation are listed below.

Poster Session:

Therapeutics and Therapeutic Models

Date:

        
        
        
        
        
        
        
        
        
        
          April 22, 2015
        
      
      
        
          

Title:

Tumor associated targeting with Manocept: HIV associated Kaposi’s sarcoma as a model system in Humans

Authors:

Rongzhen Zhang1*, Frederick O. Cope2, Toby Maurer1,3, Spencer Behr1, Paige M. Bracci1,3, Michael S. McGrath1,3

1University of California San Francisco, San Francisco, CA; 2Navidea Biopharmaceuticals/Macrophage Therapeutics, Dublin, OH; 3AIDS and Cancer Specimen Resource, San Francisco, CA. *Presenter

About Macrophage TherapeuticsMacrophage Therapeutics, a newly created subsidiary of Navidea Biopharmaceuticals, Inc. (NAVB), is developing therapeutics using the patented Manocept immunotherapy platform licensed from Navidea to target over-active macrophages implicated in cancer, cardiovascular, central nervous system, autoimmune, antiviral, and skin diseases. Manocept specifically targets CD206, or mannose receptor prevalent on over-active macrophages. The technology enables highly specific targeted delivery of active (either existing or yet to be developed) agents that can modulate the activity of over-active macrophages that have been implicated in many diseases. Targeted delivery should significantly enhance a given compound’s efficacy and safety.

About Navidea Biopharmaceuticals Inc.Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) is a commercial stage precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™, NAV4694, and NAV5001, to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and by the EMA in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea BiopharmaceuticalsInvestorsTom Baker, [e-mail] Correia, 978-655-2686Associate Director, Corporate Communications